- £1.92bn
- £993.52m
- $630.20m
- 17
- 44
- 72
- 37
REG - Hutchmed China Ltd - Total Voting Rights
AnnouncementRCS - Hutchmed China Ltd - Phase Ib/II Trial of Fruquintinib & Tislelizumab
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Selected for Certain Hang Seng Indexes
AnnouncementREG - Hutchmed China Ltd - ELECTRONIC COMMUNICATION OF CORPORATE INFORMATION
AnnouncementREG - Hutchmed China Ltd - HUTCHMED & Epizyme Announce TAZVERIK Collaboration
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementREG - Hutchmed China Ltd - Interim Results and Business Updates
AnnouncementRCS - Hutchmed China Ltd - Phase II Trial of ORPATHYS Initiated
AnnouncementREG - Hutchmed China Ltd - Stabilizing Actions & End of Stabilization Period
AnnouncementREG - Hutchmed China Ltd - Holding(s) in Company
AnnouncementRCS - Hutchmed China Ltd - Surufatinib MAA Submitted and Validated by the EMA
AnnouncementREG - Hutchmed China Ltd - Holding(s) in Company
AnnouncementRCS - Hutchmed China Ltd - First Commercial Sale of ORPATHYS® in China
AnnouncementREG - Hutchmed China Ltd - Full Exercise of the Over-allotment Option
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Initiates Phase I Trials of HMPL-295
AnnouncementREG - Hutchmed China Ltd - Holding(s) in Company
AnnouncementREG - Hutchmed China Ltd - Notice of Results
AnnouncementRCS - Hutchmed China Ltd - US FDA Accepts NDA Filing for Surufatinib
AnnouncementREG - Hutchmed China Ltd - Closing of Global Offering and Hong Kong Listing
Announcement